Nefazodone in the adjunctive therapy of schizophrenia: An open-label exploratory study

Clinical Neuropharmacology

Volumn 23, Issue 4, 2000, Pages 222-225

  Rosenberg, Paul B ^a   Rosse, Richard B ^a   Schwartz, Barbara L ^a   Deutsch, Stephen I ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Atypical antipsychotic drugs; Nefazodone; Schizophrenia; Serotonin receptor; Typical antipsychotic drugs

Indexed keywords

DOPAMINE 2 RECEPTOR; NEFAZODONE; NEUROLEPTIC AGENT; SEROTONIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRIAZOLES;

EID: 0033797366     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200007000-00011     Document Type: Article

References (28)

1. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values
2. Switching from depot antipsychotics to risperidone
3. Olanzapine vs. haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
4. The psychosis of schizophrenia: Prevalence, response to atypical antipsychotics, and prediction of outcome
5. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
6. Preclinical pharmacology of neuroleptics: Focus on new generation compounds
7. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
8. 2 dopamine receptors in 56 schizophrenia patients taking various neuroleptics
9. Relapse following clozapine withdrawal: Effect of neuroleptic drugs and cyproheptadine
10. Adjunctive trazodone in the treatment of negative symptoms of schizophrenia
11. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: An add-on, double-blind, placebo-controlled study
12. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studies
13. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
14. Nefazodone: Preclinical pharmacology of a new antidepressant
15. Nefazodone and imipramine in major depression: A placebo-controlled trial
16. A double-blind comparison of nefazodone imipramine, and placebo in major depression
17. Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: An open prospective pilot study
18. The brief psychiatric rating scale
19. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: Relationship to symptom specificity
20. Negative symptoms in schizophrenia: Definition and validation
21. Negative versus positive schizophrenia: Definition and validation
22. A new depression scale designed to be sensitive to change
23. Depressive symptoms in acute schizophrenia
24. Depression and social adjustment among chronic schizophrenic outpatients
25. Schizophrenic patients with depression: Psychopathological profiles and relationship with negative symptoms
26. Clinical correlates of memory in schizophrenia: Differential links between depression, positive and negative symptoms, and two types of memory impairment
27. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions
28. m-Chlorphenylpiperzine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia